A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial

Axel Le Cesne; Jean Yves Blay; Didier Cupissol; Antoîne Italiano; Corinne Delcambre; Nicolas Penel; Nicolás Isambert; Christine Chevreau; Emmanuelle Bompas; François Bertucci; L. Chaigneau; Sophie Piperno‐Neumann; Sébastien Salas; María Rios; Cécile Guillemet; Jacques‐Olivier Bay; Isabelle Ray‐Coquard; L. Haddag; Julia Bonastre; Raïssa Kapso; Aldéric Fraslin; Nathalie Bouvet; Olivier Mir; Stéphanie Foulon

doi:10.1016/j.annonc.2021.04.014

Related publications

Article2025

Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study

Paul Sargos, M.-P. Sunyach, Anne Ducassou, C. Llacer, D. Dinart, Audrey Michot, Thibaud Valentin, Nelly Firmin, Jean Yves Blay, P. Gillon, Carine Bellera, Antoine Italiano

Article2017

KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.

Richard S. Finn, Stephen L. Chan, Andrew X. Zhu, Jennifer J. Knox, Ann‐Lii Cheng, Abby B. Siegel, Oliver Bautista, P.A. Watson, Masatoshi Kudo

Article2020

Preliminary Results of a Phase Ib Study of Olaparib with Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-Tissue Sarcoma from the French Sarcoma Group

Paul Sargos, M.-P. Sunyach, Anne Ducassou, C. Llacer, Carine Bellera, Audrey Michot, Thibaud Valentin, Nelly Firmin, Jean Yves Blay, Derek Dinart, Antoîne Italiano

Article2022

Preliminary results of a phase IB study of olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma from the French Sarcoma Group.

Paul Sargos, Marie Pierre Sunyach, Anne Ducassou, C. Llacer, Carine Bellera, Audrey Michot, Thibaud Valentin, Nelly Firmin, Jean Yves Blay, Derek Dinart, Antoîne Italiano

Article2020

Prognostic role of MRP1 in localized high-risk soft tissue sarcoma (STS): Translational research associated to randomized phase III trial (ISG-STS 1001).

Javier Martín‐Broto, David S. Moura, Rafael Ramos, Luca Braglia, Paola Collini, Salvatore Lorenzo Renne, Cleofé Romagosa, Jean Michel Coindre, Valérie Velasco, Domenico Franco Merlo, Emanuela Palmerini, Silvia Stacchiotti, Vittorio Quagliuolo, Antonio López–Pousa, Giovanni Grignani, Jean Yves Blay, Antonella Brunello, Piero Picci, Paolo G. Casali, Alessandro Gronchi